Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aprea Therapeutics Inc (NQ: APRE ) 3.972 UNCHANGED Streaming Delayed Price Updated: 1:52 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Aprea Therapeutics Inc < Previous 1 2 Next > Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics October 23, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit October 14, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics October 10, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development October 09, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 September 25, 2024 From Aprea Therapeutics Via GlobeNewswire Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing September 20, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Life Sciences Virtual Investor Forum Agenda Announced for September 19th September 16, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 September 12, 2024 Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference September 09, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference September 09, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference August 28, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 June 21, 2024 Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 June 17, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial May 28, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update May 14, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference May 13, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 02, 2024 New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 April 10, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update March 26, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million March 11, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers March 11, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 March 05, 2024 Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor February 06, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 January 30, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 January 04, 2024 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update November 09, 2023 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways October 24, 2023 Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET From Aprea Therapeutics Via GlobeNewswire Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio October 16, 2023 From Aprea Therapeutics Via GlobeNewswire Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman August 24, 2023 From Aprea Therapeutics Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
